Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Titel:
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Auteur:
Bar-Or, Amit Thanei, Gian-Andrea Harp, Christopher Bernasconi, Corrado Bonati, Ulrike Cross, Anne H. Fischer, Saloumeh Gaetano, Laura Hauser, Stephen L. Hendricks, Robert Kappos, Ludwig Kuhle, Jens Leppert, David Model, Fabian Sauter, Annette Koendgen, Harold Jia, Xiaoming Herman, Ann E.